3. Jazz Pharmaceuticals ( JAZZ) is a specialty pharmaceutical company with two products: Xyrem and Luvox CR. Jazz will announce third-quarter results on Nov. 1. For the third quarter of 2011, net income is seen increasing to $40.60 million from $17.25 million in the year-ago quarter. Earnings per share are estimated at 92 cents, up from 41 cents in the prior-year period. Sales are seen rising 61% to $72.18 million from $44.75 million in the same quarter prior year. Gross margin is likely to expand to 94.73% from 93.09% in the year-ago period. Of the six analysts covering the stock, four recommend a buy and two suggest a hold. Analysts polled by Bloomberg expect the stock to gain almost 34.2% to $53.50 from current levels over the next 12 months.